| Dr Jonathan Samuel Figueroa, MD | |
|
934 Manhattan Ave, Brooklyn, NY 11222-5928 | |
| (718) 389-8585 | |
| Not Available |
| Full Name | Dr Jonathan Samuel Figueroa |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 934 Manhattan Ave, Brooklyn, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225525264 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 322661 (New York) | Primary |
| Entity Name | Nyu Langone Hospitals |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790975944 PECOS PAC ID: 4981515699 Enrollment ID: O20050721000058 |
News Archive
A new study has been released on the bioRxiv* preprint server, which deals with a comprehensive survey on alternative splicing concerning SARS-CoV-2 infection. This study has also included two other betacoronavirurses (SARS-CoV and MERS), a control set of unrelated viruses, and a bacterium, namely, Streptococcus pneumonia. The study findings suggest that several cellular parameters are affected owing to a betacoronavirus infection, which in turn affects some genes and invariably various biological functions.
Richard Thaler, a professor at Chicago University, and a key adviser to the British Prime Minister on behavioural economics has suggested that large group of drinkers should forgo the long-standing tradition where each one has to buy a drink for the entire party in order to stop binge drinking. This is a part of the "nudge policy."
Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country's first gene therapy, Novartis' Kymriah, a leukemia treatment approved in August.
Ethnic group and gender both influence patients' experiences with treatment decision-making but in different ways, according to new research led by Henry S. Perkins, MD, of the University of Texas Health Science Center and the Ecumenical Center for Religion and Health in San Antonio, Texas.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company's Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT).
› Verified 9 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
A new study has been released on the bioRxiv* preprint server, which deals with a comprehensive survey on alternative splicing concerning SARS-CoV-2 infection. This study has also included two other betacoronavirurses (SARS-CoV and MERS), a control set of unrelated viruses, and a bacterium, namely, Streptococcus pneumonia. The study findings suggest that several cellular parameters are affected owing to a betacoronavirus infection, which in turn affects some genes and invariably various biological functions.
Richard Thaler, a professor at Chicago University, and a key adviser to the British Prime Minister on behavioural economics has suggested that large group of drinkers should forgo the long-standing tradition where each one has to buy a drink for the entire party in order to stop binge drinking. This is a part of the "nudge policy."
Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country's first gene therapy, Novartis' Kymriah, a leukemia treatment approved in August.
Ethnic group and gender both influence patients' experiences with treatment decision-making but in different ways, according to new research led by Henry S. Perkins, MD, of the University of Texas Health Science Center and the Ecumenical Center for Religion and Health in San Antonio, Texas.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company's Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan Samuel Figueroa, MD 934 Manhattan Ave, Brooklyn, NY 11222-5928 Ph: (718) 389-8585 | Dr Jonathan Samuel Figueroa, MD 934 Manhattan Ave, Brooklyn, NY 11222-5928 Ph: (718) 389-8585 |
News Archive
A new study has been released on the bioRxiv* preprint server, which deals with a comprehensive survey on alternative splicing concerning SARS-CoV-2 infection. This study has also included two other betacoronavirurses (SARS-CoV and MERS), a control set of unrelated viruses, and a bacterium, namely, Streptococcus pneumonia. The study findings suggest that several cellular parameters are affected owing to a betacoronavirus infection, which in turn affects some genes and invariably various biological functions.
Richard Thaler, a professor at Chicago University, and a key adviser to the British Prime Minister on behavioural economics has suggested that large group of drinkers should forgo the long-standing tradition where each one has to buy a drink for the entire party in order to stop binge drinking. This is a part of the "nudge policy."
Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country's first gene therapy, Novartis' Kymriah, a leukemia treatment approved in August.
Ethnic group and gender both influence patients' experiences with treatment decision-making but in different ways, according to new research led by Henry S. Perkins, MD, of the University of Texas Health Science Center and the Ecumenical Center for Religion and Health in San Antonio, Texas.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company's Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT).
› Verified 9 days ago
Dr. Alexander Usorov, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 447 Atlantic Ave, Brooklyn, NY 11217 Phone: 718-858-6300 | |
Dr. Marcellus Andre Walker, MD Endocrinology, Diabetes & Metabolism Medicare: May Accept Medicare Assignments Practice Location: 2094 Pitkin Ave, Brooklyn, NY 11207 Phone: 718-240-0516 Fax: 718-240-0564 | |
Lotus Ahmed, D.O Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 518 Mcdonald Ave, Brooklyn, NY 11218 Phone: 917-848-5432 Fax: 347-252-6754 | |
Mrs. Sophia Schwartzman, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2700 Ocean Avenue, Brooklyn, NY 11229 Phone: 518-587-1141 | |
Dr. Haitham M Ahmed, MD, MPH Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 101 Pennsylvania Avenue, Brooklyn, NY 11207 Phone: 718-240-2000 Fax: 718-240-2260 | |
Yanjin Yang, Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-3000 | |
Ashwad Afzal, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-5246 |